Affinage

ACVR2A

Activin receptor type-2A · UniProt P27037

Length
513 aa
Mass
57.8 kDa
Annotated
2026-04-28
55 papers in source corpus 20 papers cited in narrative 20 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ACVR2A is a type II serine/threonine kinase receptor that serves as a central signaling hub for activin, BMP, and GDF ligands, transducing signals through SMAD2/3 and SMAD1/5/8 pathways to regulate tissue development, endocrine function, and tumor suppression. ACVR2A binds activin A, activin B, and GDF11 with high affinity via a conserved hydrophobic interface and assembles ligand-mediated heteromeric complexes with type I receptors (ALK4 for SMAD2/3 signaling; ALK2/3/6 for SMAD1/5/8 signaling) without direct type I–type II receptor contact, where competition among type I receptors for ACVR2A binding balances the two SMAD branches (PMID:12667445, PMID:35177083, PMID:35643319). ACVR2A-dependent activin/SMAD2/3 signaling is the primary pathway for FSH production in pituitary gonadotropes, negatively regulates osteoblast differentiation and bone mass, and suppresses epithelial-to-mesenchymal transition in colon cancer, while ACVR2A-dependent BMP/SMAD1/5 signaling is essential for endometrial receptivity and embryo implantation (PMID:32270195, PMID:28659341, PMID:37378449, PMID:34099644). Biallelic frameshift mutations in poly(A) tracts of ACVR2A are recurrently selected in microsatellite-unstable colorectal and pancreatic cancers, establishing ACVR2A as a tumor suppressor whose loss abrogates SMAD2 signaling and promotes metastasis and immune evasion (PMID:12615714, PMID:15520171, PMID:40139191).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2003 High

    Structural determination of how ACVR2A assembles signaling complexes resolved the question of whether type I and type II receptor ectodomains directly contact each other, showing instead that BMP7/ACVR2A binding allosterically increases type I receptor affinity through a ligand-mediated cooperative mechanism.

    Evidence X-ray crystallography of BMP7/ActRII ECD complex with cell membrane assembly assays and affinity measurements

    PMID:12667445

    Open questions at the time
    • Full-length receptor complex structure not resolved
    • Cooperative assembly mechanism for activin ligands not structurally characterized
    • Stoichiometry in native membrane not determined
  2. 2003 High

    The identification of recurrent biallelic frameshift mutations in ACVR2A poly(A) tracts in MSI cancers established it as a bona fide tumor suppressor gene under positive selection during tumorigenesis, raising the question of which downstream pathway mediates its growth-suppressive function.

    Evidence Sequencing and LOH analysis of MSI colorectal and pancreatic tumor cohorts (25/28 biallelic)

    PMID:12615714

    Open questions at the time
    • Functional consequence of mutations not yet tested at time of discovery
    • Whether mutations drive tumorigenesis or are passenger events in MSI context
  3. 2004 High

    Reconstitution of wild-type ACVR2A in MSI colon cancer cells directly answered which signaling pathway is lost: SMAD2 phosphorylation was restored, growth was suppressed, and AP-1 and small GTPase effectors were induced, connecting ACVR2A loss to deregulation of the activin/SMAD2 axis.

    Evidence Wild-type ACVR2A transfection into mutant colon cancer cells with Western blot for pSMAD2, microarray, and growth assays

    PMID:15520171

    Open questions at the time
    • Whether SMAD2 is the sole mediator or SMAD3 also contributes
    • In vivo tumor suppression not demonstrated
  4. 2005 Medium

    Morpholino knockdown in zebrafish established that ACVR2A has non-redundant developmental roles distinct from ACVR2B, specifically in cranial neural crest–derived craniofacial structures.

    Evidence Morpholino knockdown in zebrafish with craniofacial phenotypic analysis

    PMID:15977175

    Open questions at the time
    • Morpholino off-target effects not ruled out by genetic mutant
    • Downstream signaling branch (SMAD2/3 vs SMAD1/5/8) in this context unknown
    • Mammalian craniofacial phenotype not tested
  5. 2015 Medium

    Activin A was shown to antagonize BMP-6/BMP-9 signaling by competing for ACVR2A/ACVR2B binding to ALK2, revealing that ACVR2A serves as a contested node where activin and BMP ligands compete for access to type I receptors.

    Evidence Receptor binding competition and BMP signaling inhibition assays in myeloma cells with defined receptor expression

    PMID:26047946

    Open questions at the time
    • Competition dynamics not quantified at endogenous receptor levels
    • In vivo relevance of BMP antagonism through ACVR2A not tested
  6. 2017 High

    Conditional knockout of ACVR2A in osteoblasts/osteocytes demonstrated that ACVR2A directly and negatively regulates bone mass via activin/SMAD2/3, answering whether ACVR2A functions cell-autonomously in bone and distinguishing it from ACVR2B.

    Evidence Osteocalcin-Cre conditional knockout mice; primary osteoblast cultures; micro-CT; alkaline phosphatase activity

    PMID:28659341

    Open questions at the time
    • Identity of the endogenous ligand (activin A vs. other) driving bone phenotype not resolved
    • Whether ACVR2A also signals through SMAD1/5/8 in osteoblasts not tested
  7. 2020 High

    Gonadotrope-specific knockout established ACVR2A as the dominant type II receptor for activin-stimulated FSH production, with ACVR2B playing an additive but secondary role, resolving receptor usage hierarchy in the reproductive endocrine axis.

    Evidence Cre-lox gonadotrope-specific single and double knockout mice; serum FSH measurement; fertility phenotyping

    PMID:32270195

    Open questions at the time
    • Whether ACVR2A signals through ALK4 exclusively in gonadotropes not formally tested
    • Pulsatile regulation of FSH by ACVR2A not characterized
  8. 2021 High

    Uterine-specific deletion revealed that ACVR2A, but not ACVR2B, is essential for BMP-SMAD1/5 signaling in the endometrium and embryo implantation, establishing a tissue where ACVR2A preferentially engages the BMP/SMAD1/5 branch rather than the activin/SMAD2/3 branch.

    Evidence PR-Cre conditional knockout of ACVR2A and ACVR2B in mouse uterus; SMAD1/5 deletion phenocopy; histology and implantation assays

    PMID:34099644

    Open questions at the time
    • Which BMP ligand acts through ACVR2A in the uterus not identified
    • Type I receptor partner (ALK2/3/6) in uterine signaling not defined
  9. 2022 High

    Biophysical and structural studies resolved how ACVR2A integrates two SMAD branches at the receptor level: ALK4 and BMP type I receptors form stable complexes with ACVR2A and compete for its binding, and a crystal structure of ACVR2A with activin A defined the conserved hydrophobic binding interface and ligand specificity (activin A/B, GDF11).

    Evidence IgG-patching/FRAP in U2OS cells; Smad reporter assays; X-ray crystallography of ACVR2A/activin A complex; in vitro binding affinity measurements

    PMID:35177083 PMID:35643319

    Open questions at the time
    • Full heteromeric complex structure (type II + ligand + type I) not solved
    • Kinetic parameters of type I receptor competition at endogenous expression levels unknown
  10. 2024 High

    ACVR2A homo-dimerization was shown to be ligand-dependent (unlike ACVR2B), explaining why ACVR2A requires activin A to activate the FOP-causing ALK2-R206H mutant while ACVR2B can do so constitutively—resolving a mechanistic distinction between the two type II receptors relevant to fibrodysplasia ossificans progressiva.

    Evidence FRAP-based oligomerization measurements; pSMAD1/5/8 Western blotting; BRE-Luc reporter assays with wild-type and R206H ALK2

    PMID:38334613

    Open questions at the time
    • Structural basis of ligand-dependent versus ligand-independent dimerization not resolved
    • In vivo relevance for FOP pathogenesis not tested
  11. 2024 Medium

    ACVR2A impairment in hepatocellular carcinoma was linked to immune evasion through a SMAD-inactivation/hyperglycolysis/lactate/Treg recruitment axis, and in hepatic stellate cells ACVR2A mediates TGF-β1/SMAD-driven fibrosis, broadening its tumor-suppressive and fibrogenic roles beyond colorectal cancer.

    Evidence Syngeneic mouse models with ACVR2A knockdown; pharmacological MCT4 inhibition; siRNA/overexpression in LX-2 cells; in vivo fibrosis models

    PMID:38366962 PMID:40139191

    Open questions at the time
    • Mechanism by which SMAD inactivation upregulates LDHA/MCT4 not fully defined
    • Relative contribution of ACVR2A versus other TGF-β type II receptors in stellate cell fibrosis unclear
    • Single studies for each phenotype
  12. 2025 Medium

    CRISPR knockout of ACVR2A in trophoblast cell lines confirmed its requirement for trophoblast migration, proliferation, and invasion, and identified a TCF7/c-JUN downstream pathway, extending ACVR2A's role in placental development.

    Evidence CRISPR/Cas9 knockout in HTR8/SVneo and JAR cells; RNA-seq; functional migration/invasion assays; RT-PCR/IHC validation

    PMID:40444773

    Open questions at the time
    • In vivo placental phenotype of ACVR2A loss not demonstrated
    • Whether TCF7/c-JUN pathway is SMAD-dependent or independent not established

Open questions

Synthesis pass · forward-looking unresolved questions
  • A full-length heteromeric signaling complex structure (type II receptor + ligand + type I receptor + SMAD) remains unsolved, and the tissue-specific rules determining whether ACVR2A engages the SMAD2/3 versus SMAD1/5/8 branch are incompletely understood.
  • No full heteromeric complex crystal structure
  • Tissue-specific determinants of SMAD branch selection not systematically mapped
  • Relative contributions of ACVR2A versus ACVR2B in most tissues not genetically dissected

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 8 GO:0098772 molecular function regulator activity 2
Localization
GO:0005886 plasma membrane 3
Pathway
R-HSA-162582 Signal Transduction 8 R-HSA-1643685 Disease 4 R-HSA-1266738 Developmental Biology 2 R-HSA-1474165 Reproduction 2
Partners
ACVR2BALK2ALK3ALK4ALK6SMAD1SMAD2
Complex memberships
Activin-ACVR2A-ALK4 complexBMP-ACVR2A-ALK2/3/6 complex

Evidence

Reading pass · 20 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 Crystal structure of BMP7 in complex with the extracellular domain (ECD) of ACVR2A (activin type II receptor) revealed a four-receptor model in which type I and type II receptor ECDs make no direct contacts, yet truncated receptors lacking cytoplasmic domains retain cooperative assembly ability in the cell membrane; presence of the type II receptor ECD increases BMP7 affinity for its low-affinity type I receptor ECD 5-fold, demonstrating ligand-mediated cooperative receptor assembly. X-ray crystallography of BMP7/ActRII ECD complex; cell membrane assembly assays with truncated receptors; affinity binding measurements Molecular cell High 12667445
2003 ACVR2A (ACVR2) gene contains two 8-bp polyadenine tracts that are targets for inactivating frameshift mutations in microsatellite-unstable (MSI) gastrointestinal cancers; biallelic mutations found in 25/28 MSI colorectal and pancreatic cancers, supporting ACVR2 as a tumor suppressor gene whose inactivation is selected for during tumorigenesis. Sequencing of tumor samples; loss-of-heterozygosity analysis; identification of biallelic frameshift mutations Cancer research High 12615714
2004 Restoration of wild-type ACVR2A in ACVR2-deficient MSI-H colon cancer cells decreased cell growth and increased phosphorylated SMAD2 levels, and induced expression of AP-1 complex genes (JUND, JUN, FOSB) and small GTPase family members (RHOB, ARHE, ARHGDIA), indicating ACVR2A signals through SMAD2 phosphorylation and activates TGF-β effector pathways. Wild-type ACVR2A transfection into mutant colon cancer cells; Western blotting for pSMAD2; microarray gene expression analysis; cell growth assay Cancer research High 15520171
2005 Truncating mutations in ACVR2A in prostate cancer cell lines result in significantly reduced activin-mediated cell signaling, as demonstrated by an activin response assay, establishing that ACVR2A kinase activity is required for activin signal transduction. Sequencing of prostate cancer cell lines for ACVR2 mutations; activin response assay to measure signaling output of truncated vs. wild-type ACVR2A Cancer genetics and cytogenetics Medium 16337854
2005 In zebrafish, acvr2a morpholino knockdown causes defects in development of most cranial neural crest cell (NCC)-derived cartilage, bone, and pharyngeal tooth structures, while acvr2b morphants show distinct posterior arch defects, demonstrating distinct roles for acvr2a and acvr2b in hindbrain/NCC patterning and craniofacial development. Morpholino-based targeted protein depletion in zebrafish; phenotypic analysis of craniofacial structures Developmental dynamics Medium 15977175
2015 Activin A antagonizes BMP-6 and BMP-9 (but not BMP-2 or BMP-4) by binding to ACVR2A and ACVR2B, thereby competing with BMPs that signal through ACVR2A/ACVR2B in combination with ALK2, establishing that activin A regulates cell behavior by antagonizing BMP-ACVR2A/ACVR2B/ALK2 signaling. Receptor binding competition assays in myeloma cell lines with well-characterized BMP-receptor expression; BMP signaling inhibition assays Cell communication and signaling : CCS Medium 26047946
2017 Conditional deletion of ACVR2A (but not ACVR2B) in osteoblasts/osteocytes in mice leads to enhanced osteoblast differentiation in vitro (increased alkaline phosphatase activity, mineral deposition, osterix/osteocalcin expression) and significantly increased femoral trabecular bone volume in vivo, demonstrating that ACVR2A directly and negatively regulates bone mass in osteoblasts via activin/SMAD2/3 signaling. Conditional knockout mice (osteocalcin-Cre); primary osteoblast cultures; alkaline phosphatase activity assay; micro-CT; IHC localization of ACVR2A/ACVR2B to osteoblasts and osteocytes The Journal of biological chemistry High 28659341
2017 BMP2 signals through ALK2/ALK3 type I receptors and BMPR2/ACVR2A type II receptors to phosphorylate SMAD1/5/8, and this pathway suppresses pentraxin 3 (PTX3) expression in human granulosa-lutein cells; knockdown of ACVR2A (or BMPR2) abolished BMP2-induced SMAD1/5/8 phosphorylation and restored PTX3 expression. siRNA knockdown of ACVR2A and other receptors in human granulosa-lutein cells; Western blotting for pSMAD1/5/8; PTX3 expression measurement; BMP type I receptor inhibitor assays Endocrinology Medium 28977600
2020 Gonadotrope-specific conditional knockout of Acvr2a in mice causes marked decreases in serum FSH and subfertility/hypogonadism, and double knockout of Acvr2a and Acvr2b leads to profound FSH deficiency and sterility, demonstrating that ACVR2A is the primary type II receptor through which activins stimulate FSH production in pituitary gonadotropes. Cre-lox conditional knockout (gonadotrope-specific); serum FSH measurement; fertility and reproductive phenotype analysis Endocrinology High 32270195
2021 Conditional deletion of ACVR2A (using PR-Cre) but not ACVR2B in the mouse uterus disrupts BMP-induced SMAD1/5 signaling, causing cystic endometrial glands, hyperproliferative endometrial epithelium during the implantation window, impaired apicobasal transformation, and infertility, establishing that BMP signals through an ACVR2A-SMAD1/5 axis to promote endometrial receptivity and embryo implantation. Conditional knockout mice (PR-Cre for ACVR2A and ACVR2B, single and double); SMAD1/5 deletion mice; histological analysis; implantation and fertility assays Nature communications High 34099644
2022 ACVR2A forms stable heteromeric complexes at the plasma membrane with ALK4 (activin type I receptor) as well as with BMP type I receptors (ALK2/3/6); ALK4 and BMP type I receptors compete for binding to ACVR2A, and this competition balances signaling between the Smad2/3 and Smad1/5/8 branches. IgG-mediated patching-immobilization combined with FRAP measurements of lateral diffusion; ligand stimulation and type I receptor overexpression experiments; Smad pathway reporter assays in U2OS cells BMC biology High 35177083
2022 Crystal structure of ACVR2A in complex with activin A (and of BMPR2 with activin B) showed that ACVR2A binds growth factors with a conserved hydrophobic hot spot using nearly identical geometry to BMPR2; high-affinity GFs for ACVR2A are activin A, activin B, and GDF11, distinct from BMPR2's preferred ligands (BMP15, BMP10, Nodal). X-ray crystallography; in vitro GF binding affinity assays The Journal of biological chemistry High 35643319
2014 miR-590 directly targets Acvr2a in mouse ESCs, reducing Activin signaling and upregulating Rad51b (a homologous recombination repair gene), thereby balancing DNA damage repair and rapid proliferation during self-renewal. miR-590 overexpression; Acvr2a knockdown/targeting validation; DNA damage repair assays (SSB, DSB); cell cycle analysis in mESCs Stem cell reports Medium 25458897
2015 A promoter polymorphism (rs1424954) in ACVR2A reduces ACVR2A expression in trophoblast cells; knockdown of ACVR2A in trophoblasts causes reduced NODAL mRNA expression in response to physiologic Activin-A concentrations (suggesting increased trophoblast invasion capacity), but this protective effect is lost at pathologic Activin-A levels as seen in pre-eclampsia. Transfection of ACVR2A promoter constructs in SGHPL-5 extravillous trophoblasts; qRT-PCR; siRNA knockdown of ACVR2A Placenta Medium 25659497
2023 Activin A binding to ACVR2A activates SMAD2 (but not SMAD3) transcription and inhibits colon cancer cell migration, invasion, and epithelial-to-mesenchymal transition in vitro and in vivo; ACVR2A downregulation promotes colon cancer metastasis via loss of SMAD2 activation. In vitro migration/invasion assays; EMT marker analysis; in vivo animal experiments; mechanistic studies showing selective activin A/ACVR2A/SMAD2 activation; clinical sample analysis Molecular carcinogenesis Medium 37378449
2024 ACVR2A impairment in hepatocellular carcinoma induces hyperglycolysis through inactivation of the SMAD signaling pathway, leading to upregulation of LDHA and MCT4, increased lactate secretion, and recruitment of regulatory T cells, causing resistance to immune checkpoint inhibitors. Syngeneic transplantation mouse models; genetic knockdown and pharmacological inhibition of MCT4; human clinical sample analysis; Western blotting for SMAD pathway components Cell reports. Medicine Medium 40139191
2024 ACVR2A mediates TGF-β1/Smad signaling in hepatic stellate cells to regulate hepatic fibrosis; inhibition of ACVR2A reduces SMAD pathway activation and attenuates liver fibrosis in vivo and in vitro. Transcriptome analysis; siRNA inhibition and overexpression of ACVR2A in LX-2 hepatic stellate cells; in vivo high-fat diet mouse model; proliferation/migration assays Molecular nutrition & food research Medium 38366962
2024 ACVR2A homo-dimerization is ligand (Activin A)-dependent, in contrast to ACVR2B which forms stable homomeric complexes without ligand; ACVR2B can activate the FOP-inducing ALK2-R206H mutant without ligand, while ACVR2A-mediated activation of ALK2-R206H requires Activin A, demonstrating that homo-oligomerization patterns of ACVR2A versus ACVR2B dictate their ability to recruit and activate ALK2-R206H. IgG-mediated receptor immobilization combined with FRAP lateral diffusion measurements; pSMAD1/5/8 Western blotting; BRE-Luc transcriptional reporter assays Cells High 38334613
2025 CRISPR/Cas9 deletion of ACVR2A in trophoblast cell lines (HTR8/SVneo, JAR) inhibits trophoblast migration, proliferation, and invasion; RNA-seq revealed that ACVR2A knockout disrupts the TCF7/c-JUN pathway, which was validated by RT-PCR and immunohistochemistry. CRISPR/Cas9 knockout; functional migration/proliferation/invasion assays; RNA-seq; RT-PCR; immunohistochemistry eLife Medium 40444773
2018 miR-590 targets Acvr2a in mouse pre-iPSCs; downregulation of Acvr2a promotes telomere elongation and pluripotency by reducing pSMAD2 binding to the Terf1 promoter, thereby increasing Terf1 expression; this defines a miR-590/Acvr2a/Terf1 signaling axis in iPSC reprogramming. miR-590 overexpression; Acvr2a shRNA knockdown; chromatin immunoprecipitation (ChIP) for pSMAD2 at Terf1 promoter; telomere length measurement; pluripotency assays in pre-iPSCs Stem cell reports Medium 29910124

Source papers

Stage 0 corpus · 55 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2003 The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Molecular cell 224 12667445
2019 Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis. Molecular cancer 133 31101108
2015 Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. Cell communication and signaling : CCS 129 26047946
2003 Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Cancer research 98 12615714
2021 Endometrial receptivity and implantation require uterine BMP signaling through an ACVR2A-SMAD1/SMAD5 axis. Nature communications 70 34099644
2016 ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skeletal muscle 70 27462398
2017 Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass. The Journal of biological chemistry 54 28659341
2008 Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study). European journal of human genetics : EJHG 51 18781190
2012 BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II. Angiogenesis 43 22622516
2004 Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes. Cancer research 37 15520171
2009 Genetic association of the activin A receptor gene (ACVR2A) and pre-eclampsia. Molecular human reproduction 32 19126782
2017 ALK2/ALK3-BMPR2/ACVR2A Mediate BMP2-Induced Downregulation of Pentraxin 3 Expression in Human Granulosa-Lutein Cells. Endocrinology 29 28977600
2014 A miR-590/Acvr2a/Rad51b axis regulates DNA damage repair during mESC proliferation. Stem cell reports 27 25458897
2003 The interaction of BMP-7 and ActRII implicates a new mode of receptor assembly. Trends in biochemical sciences 25 14559178
2005 Zebrafish acvr2a and acvr2b exhibit distinct roles in craniofacial development. Developmental dynamics : an official publication of the American Association of Anatomists 24 15977175
2005 Truncating mutations in the ACVR2 gene attenuates activin signaling in prostate cancer cells. Cancer genetics and cytogenetics 24 16337854
2022 Competition between type I activin and BMP receptors for binding to ACVR2A regulates signaling to distinct Smad pathways. BMC biology 23 35177083
2020 Murine FSH Production Depends on the Activin Type II Receptors ACVR2A and ACVR2B. Endocrinology 22 32270195
2019 Comparative analysis of silencing expression of myostatin (MSTN) and its two receptors (ACVR2A and ACVR2B) genes affecting growth traits in knock down chicken. Scientific reports 22 31127166
2008 Mutation rates of TGFBR2 and ACVR2 coding microsatellites in human cells with defective DNA mismatch repair. PloS one 22 18941508
2024 Circular RNA ACVR2A promotes the progression of hepatocellular carcinoma through mir-511-5p targeting PI3K-Akt signaling pathway. Molecular cancer 21 39107843
2014 Association between ACVR2A and early-onset preeclampsia: replication study in a Northeastern Brazilian population. Placenta 20 25499008
2006 Involvement of the bone morphogenetic protein/receptor system during follicle development in the bovine ovary: Hormonal regulation of the expression of bone morphogenetic protein 7 (BMP-7) and its receptors (ActRII and ALK-2). Molecular and cellular endocrinology 20 16513253
2018 Detection of the Human Anti-ActRII Antibody Bimagrumab in Serum by Means of Affinity Purification, Tryptic Digestion, and LC-HRMS. Proteomics. Clinical applications 17 29226558
2018 Combined detection of the ActRII-Fc fusion proteins Sotatercept (ActRIIA-Fc) and Luspatercept (modified ActRIIB-Fc) in serum by means of immunoaffinity purification, tryptic digestion, and LC-MS/MS. Drug testing and analysis 16 30285318
2003 Loss of heterozygosity and mutational analyses of the ACTRII gene locus in human colorectal tumors. Laboratory investigation; a journal of technical methods and pathology 14 14691305
2025 ACVR2A attenuation impacts lactate production and hyperglycolytic conditions attracting regulatory T cells in hepatocellular carcinoma. Cell reports. Medicine 13 40139191
2022 Downregulation of miR-192 Alleviates Oxidative Stress-Induced Porcine Granulosa Cell Injury by Directly Targeting Acvr2a. Cells 13 35954205
2020 Microsatellite Instability-Related ACVR2A Mutations Partially Account for Decreased Lymph Node Metastasis in MSI-H Gastric Cancers. OncoTargets and therapy 11 32440149
2015 ACVR2A promoter polymorphism rs1424954 in the Activin-A signaling pathway in trophoblasts. Placenta 11 25659497
2011 Association of the rs1424954 polymorphism of the ACVR2A gene with the risk of pre-eclampsia is not replicated in a Finnish study population. BMC research notes 11 22177086
2018 Targeted sequencing analysis of ACVR2A gene identifies novel risk variants associated with preeclampsia. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 10 29506428
2018 Association between 3'UTR polymorphisms in genes ACVR2A, AGTR1 and RGS2 and preeclampsia. General physiology and biophysics 10 29593124
2022 Type II BMP and activin receptors BMPR2 and ACVR2A share a conserved mode of growth factor recognition. The Journal of biological chemistry 9 35643319
2024 Echinacoside Exerts Antihepatic Fibrosis Effects in High-Fat Mice Model by Modulating the ACVR2A-Smad Pathway. Molecular nutrition & food research 8 38366962
2023 Activin A/ACVR2A axis inhibits epithelial-to-mesenchymal transition in colon cancer by activating SMAD2. Molecular carcinogenesis 8 37378449
2019 Does the expression of the ACVR2A gene affect the development of colorectal cancer? Genetics and molecular biology 8 30856244
2019 Association between ACVR2A gene polymorphisms and risk of hypertensive disorders of pregnancy in the northern Chinese population. Placenta 8 31790936
2017 Decidual ACVR2A regulates extravillous trophoblast functions of adhesion, proliferation, migration and invasion in vitro. Pregnancy hypertension 8 29203340
2011 Identification of Acvr2a as a Th17 cell-specific gene induced during Th17 differentiation. Bioscience, biotechnology, and biochemistry 8 22056434
2025 ActRII or BMPR ligands inhibit skeletal myoblast differentiation, and BMPs promote heterotopic ossification in skeletal muscles in mice. Skeletal muscle 7 39994804
2018 The miR-590/Acvr2a/Terf1 Axis Regulates Telomere Elongation and Pluripotency of Mouse iPSCs. Stem cell reports 7 29910124
2024 Sponging of five tumour suppressor miRNAs by lncRNA-KCNQ1OT1 activates BMPR1A/BMPR1B-ACVR2A/ACVR2B signalling and promotes chemoresistance in hepatocellular carcinoma. Cell death discovery 6 38851743
2011 Flanking nucleotide specificity for DNA mismatch repair-deficient frameshifts within activin receptor 2 (ACVR2). Mutation research 6 22001236
2021 Isolated and Sporadic Human Mesiodens Is Associated with a Synonymous Variant in the ACVR2A Gene. Pediatric dentistry 5 33662249
2019 Non-additive effects of ACVR2A in preeclampsia in a Philippine population. BMC pregnancy and childbirth 5 30621627
2022 CircRNA ACVR2A Sponges miR-1290 to Modulate Cell Progression in Gastric Cancer. Journal of oncology 3 35186081
2025 ACVR2A facilitates trophoblast cell invasion through TCF7/c-JUN pathway in pre-eclampsia progression. eLife 2 40444773
2024 The Activation of the Fibrodysplasia Ossificans Progressiva-Inducing ALK2-R206H Mutant Depends on the Distinct Homo-Oligomerization Patterns of ACVR2B and ACVR2A. Cells 2 38334613
2024 Identification of 8 candidate microsatellite instability loci in colorectal cancer and validation of the ACVR2A mechanism in the tumor progression. Scientific reports 2 38898042
1996 Cloning of the bovine activin receptor type II gene (ACVR2) and mapping to chromosome 2 (BTA2). Cytogenetics and cell genetics 1 8995483
2025 The First Evidence for the Role of ACVR2A Gene Fetal Genotype in Preeclampsia Susceptibility. Molecular genetics & genomic medicine 0 39898504
2025 A Novel ACVR2A::RAF1 Fusion in Spindle Cell Sarcoma. Genes, chromosomes & cancer 0 39950347
2023 Characterization of Fibrodysplasia Ossificans Progessiva relevant Acvr1/Acvr2 Activin receptors in medaka (Oryzias latipes). PloS one 0 37708126
2022 BAT25, ACVR2, and TGFBR2 Mononucleotide STR Markers: A Triplex Panel for Microsatellite Instability Testing in Colorectal Tumors. Advanced biomedical research 0 36393819